ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1612

Factors Associated with COVID-19 Vaccine Hesitancy Among Individuals with Rheumatic Disease
Abstract Number: 1602

Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City
Abstract Number: 1297

Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study
Abstract Number: 0361

Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Abstract Number: 1141

Factors Associated with Fragility Fracture in Patients with Systemic Mastocytosis: Data from an Inception Cohort in a Single Centre
Abstract Number: 0360

Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Abstract Number: 0476

Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis
Abstract Number: 1723

Factors Associated with Postpartum Flare in Women with Lupus
Abstract Number: 0437

Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Abstract Number: 0936

Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
Abstract Number: 1256

Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 1026

Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Abstract Number: 0409

Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis
Abstract Number: 1260

Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
Abstract Number: 0392

Faecal Incontinence in Scleroderma: Prevalence, Impact and Response to Sacral Neuromodulation in an Single Centre Observational Cohort
Abstract Number: 1849

False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center
Abstract Number: PP09

Family Planning while Living with Rheumatoid Arthritis
Abstract Number: 1437

Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis
Abstract Number: 0230

Fatigue and Inflammation in Rheumatoid Arthritis Are Already Disconnected Before Clinical Arthritis Develops
Abstract Number: 1678

Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Abstract Number: 0233

Feasibility and Acceptability of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Abstract Number: 1052

Female Reproductive Factors and Risk of Joint Replacement Arthroplasty of the Knee and Hip Due to Osteoarthritis in Postmenopausal Women: A Nationwide Cohort Study of 1.36 Million Women
Abstract Number: 0510

Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes
Abstract Number: 0120

Fibromyalgianess and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis
Abstract Number: PP12

Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Abstract Number: PP05

Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
Abstract Number: 0928

Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis
Abstract Number: 0069

First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (
Abstract Number: 0242

FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study
Abstract Number: 0099

First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Abstract Number: 1288

First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Abstract Number: 1771

First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8
Abstract Number: 1262

Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
Abstract Number: 0836

Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis
Abstract Number: 1550

Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Abstract Number: 0117

Flares Following Herpes Zoster Recombinant Zoster Vaccination Among Adults Age ≥50 Years with Immune Mediated Inflammatory Diseases in the United States
Abstract Number: 0698

Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue
Abstract Number: 0644

Follow-up Scheduling Appears Essential for Success of Rheumatology High Blood Pressure Protocol Across Health Systems
Abstract Number: 1142

For Vulnerable Population Treated at a Community Health Center (CHC), Primary Care Physician (PCP) Turnover Should Be Included in Social Determinants of Health (SDH) on Non-completing Osteoporosis Treatment
Abstract Number: 1139

Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Abstract Number: 1140

Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Abstract Number: 1267

Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Abstract Number: 0078

Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Abstract Number: 1210

Frequency of Anterior Atlanto-Axial Subluxation in Patients with Rheumatoid Arthritis
Abstract Number: 0483

Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
Abstract Number: 0542

Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis
Abstract Number: 0456

Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus
Abstract Number: 1494

Functional Effects of a Lupus-associated PRKG1 Variant on the RhoA-ROCK Pathway and Response to Type I Interferon
Abstract Number: 1838

Further Construct Validation of the

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].